X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
1. Salicylate, Sodium
1. 54-21-7
2. Sodium 2-hydroxybenzoate
3. Enterosalicyl
4. Kerasalicyl
5. Clin
6. Alysine
7. Salsonin
8. Benzoic Acid, 2-hydroxy-, Monosodium Salt
9. Enterosalil
10. Entrosalyl
11. Glutosalyl
12. Magsalyl
13. Aroall
14. Kerosal
15. Nadisal
16. Salisod
17. Idocyl Novum
18. Neo-salicyl
19. Natrum Salicylicum
20. Monosodium Salicylate
21. Salicylic Acid Sodium Salt
22. Diuretin
23. Parbocyl-rev
24. Sodium;2-hydroxybenzoate
25. Salicylate Sodium
26. Salicylic Acid, Sodium Salt
27. Sodium O-hydroxybenzoate
28. Salicylic Acid Sodium
29. Wiq1h85syp
30. O-hydroxybenzoic Acid, Sodium Salt
31. Chebi:9180
32. Nsc-202167
33. 90218-97-6
34. Benzoic Acid, 2-hydroxy-, Monosodium Salt, Coupled With 4-amino-1-naphthalenesulfonic Acid And Diazotized 2-(4-aminophenyl)-1h-benzimidazol-5-amine, Sodium Salt
35. Salicylic Acid Sodium Salt;2-hydroxybenzoic Acid Sodium Salt
36. Natrium Salicylat [german]
37. Ccris 6715
38. Einecs 200-198-0
39. Unii-wiq1h85syp
40. Nsc 202167
41. Sodium Salicylate [usp:jan]
42. Natrii Salicylas
43. Mfcd00002440
44. Sodium;2-carboxyphenolate
45. Sodium Salicylate, 99%
46. Spectrum2_001945
47. Spectrum3_000900
48. Spectrum4_000995
49. Spectrum5_001120
50. Dsstox_cid_1708
51. Ec 200-198-0
52. Schembl4603
53. Dsstox_rid_76287
54. Dsstox_gsid_21708
55. Kbiogr_001429
56. 90218-94-3
57. Spectrum1500533
58. Spbio_002009
59. Chembl447868
60. Sodium Salicylate [jan]
61. Dtxsid5021708
62. Sodium Salicylate (jp17/usp)
63. Sodium Salicylate [inci]
64. Hy-b0167a
65. Kbio3_001820
66. Natrum Salicylicum [hpus]
67. Sodium Salicylate [vandf]
68. Sodium Salicylate [mart.]
69. Hms1920p16
70. Hms2092g17
71. Salicylate Sodium [who-dd]
72. Sodium Salicylate [usp-rs]
73. Sodium Salicylate [who-ip]
74. Sodium Salicylate, P.a., 99.5%
75. Tox21_200411
76. 2-hydroxy Benzoic Acid, Sodium Salt
77. Ccg-39474
78. Akos003051698
79. Akos005766021
80. Cs-2008
81. Cas-54-21-7
82. Natrii Salicylas [who-ip Latin]
83. Salicylic Acid Sodium Salt [mi]
84. Sodium Salicylate [ep Monograph]
85. Ncgc00094780-01
86. Ncgc00094780-02
87. Ncgc00257965-01
88. Sodium Salicylate [usp Monograph]
89. Db-052516
90. Ft-0631235
91. C07587
92. D00566
93. D83111
94. Sodium Salicylate, Reagentplus(r), >=99.5%
95. Sodium Salicylate, Saj First Grade, >=99.5%
96. Sodium Salicylate, Tested According To Ph.eur.
97. Sodium Salicylate, Saj Special Grade, >=99.5%
98. 2,4-dimethoxyphenylboronicacid,pinacolester
99. Q414547
100. Sodium Salicylate, Vetec(tm) Reagent Grade, 99%
101. Sodium Salicylate, Meets Usp Testing Specifications
102. Sodium Salicylate, Puriss. P.a., >=99.5% (nt)
103. Sodium Salicylate, European Pharmacopoeia (ep) Reference Standard
104. Sodium Salicylate, United States Pharmacopeia (usp) Reference Standard
105. Benzoic Acid,2-hydroxy-,monosodium Salt,coupled With 4-amino-5-hydroxy-2,7-naphthalenedisulfonic Acid,diazotized 2-(4-aminophenyl)-1h-benzimidazol-5-amine And Diazotized 4-nitrobenzenamine,sodium
106. Sodium Salicylate, Puriss. P.a., Reag. Ph. Eur., 99.5-101.0% (calc. To The Dried Substance)
| Molecular Weight | 160.10 g/mol |
|---|---|
| Molecular Formula | C7H5NaO3 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 1 |
| Exact Mass | 160.01363830 g/mol |
| Monoisotopic Mass | 160.01363830 g/mol |
| Topological Polar Surface Area | 60.4 Ų |
| Heavy Atom Count | 11 |
| Formal Charge | 0 |
| Complexity | 138 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Anti-Inflammatory Agents, Non-Steroidal
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)
Cyclooxygenase Inhibitors
Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes. (See all compounds classified as Cyclooxygenase Inhibitors.)
N - Nervous system
N02 - Analgesics
N02B - Other analgesics and antipyretics
N02BA - Salicylic acid and derivatives
N02BA04 - Sodium salicylate
Market Place
